Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
The move contributed to a net position change of about $10.9 million from the previous quarter. As of September 30, Aristotle Capital Boston reported holding 305,273 SUPN shares valued at $14.6 million. These 10 stocks could mint the next wave of millionaires › Aristotle Capital Boston disclosed in a November 14 SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals (NASDAQ:SUPN) , contributing to a reduction in its position by about $10.9 million. According to a Securities and Exchange Commission (SEC) filing dated November 14, Aristotle Capital Boston reduced its holdings in Supernus Pharmaceuticals (NASDAQ:SUPN) by 503,122 shares in the third quarter. The fund's overall position decreased to 305,273 shares with a reported value of $14.6 million as of September 30. The estimated value of shares sold was approximately $10.9 million. Supernus represents about 0.75% of 13F AUM as of September 30. Top holdings after the filing: NASDAQ:HURN: $54 million (2.8% o
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in CanadaBusiness Wire
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual ConferenceGlobeNewswire
- Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SUPN
Earnings
- 11/4/25 - Miss
SUPN
Sec Filings
- 11/24/25 - Form 4
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- SUPN's page on the SEC website